중등도-중증의 한국인 건선 환자에서 Ustekinumab 장기 투여에 따른 효과 및 안전성 연구
Long-Term Analysis of Ustekinumab Therapy for Moderate-to-Severe Psoriasis in Korea
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCIScopus
- 저널 순위
- Scopus Q4KCI Q3
- 저널
- 대한피부과학회지60(3) · pp.151 · 2022
- 피인용
- Scopus 0KCI 0
- FWCI (Scopus)
- 0
- ISSN
- 0494-4739
저자
- 김연아제1저자Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea
- 배경남Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
- 손진화Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
- 신기혁Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
- 김훈수Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
- 고현창Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
- 김문범Department of Dermatology, Pusan National University School of Medicine, Busan, Korea
- 신봉석Department of Dermatology, Chosun University School of Medicine, Gwangju, Korea
- 김병수교신저자Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
초록
Background: Ustekinumab is a humanized monoclonal antibody targeting interleukin (IL)-12 and IL-23. Although popular, data on its long-term efficacy and safety in Korean patients with psoriasis are limited. Objective: To evaluate the long-term efficacy and safety of ustekinumab in Korean patients with psoriasis. Methods: A retrospective study in patients with moderate-to-severe psoriasis who had been treated with ustekinumab for at least 5 years was conducted. The sex, age, body mass index, medical records, previous psoriasis therapy, psoriasis area and severity index (PASI) scores, and adverse events were evaluated. Results: Twenty-five patients (median age 47.00 years) had been treated with ustekinumab for 5 years. The mean duration of psoriasis was 19.12±8.45 years, and the treatment duration with ustekinumab was 285.12±8.48 weeks. The baseline PASI was 17.52±7.38. PASI75 was achieved in 84% of the patients at week 28, and 96% of the patients maintained PASI75 during the 5-year follow-up period. Furthermore, 56% of patients reached PASI90 at 28 weeks, and 48% of patients maintained PASI90 for 5 years. No unexpected adverse events other than herpes zoster, herpes simplex, or elevated liver enzymes were reported. Conclusion: Ustekinumab demonstrated long-lasting efficacy with an acceptable safety profile in Korean patients with moderate-to-severe psoriasis.
키워드
식별자
- Scopus EID
- 2-s2.0-85134297538
- KCI
- ART002825534



로그인
연구물 목록으로